Michael P. Duggan, Evangelos D. Katsanos, Hassan Hamandi. The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. // Journal of Pediatric Gastroenterology and Nutrition. – 2026. – DOI: 10.1002/jpn3.70534. – URL: https://onlinelibrary.wiley.com/doi/10.1002/jpn3.70534?af=R
Michael P. Duggan, Evangelos D. Katsanos, & Hassan Hamandi (2026). The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70534
Michael P. Duggan, et al. “The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease.” Journal of Pediatric Gastroenterology and Nutrition, 2026. doi:10.1002/jpn3.70534.
@article{Duggan2026,
title = {The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease},
author = {Duggan, Michael P. and Katsanos, Evangelos D. and Hamandi, Hassan},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70534},
url = {https://onlinelibrary.wiley.com/doi/10.1002/jpn3.70534?af=R}
}
ABSTRACT Aim To investigate the longitudinal association between early‐life movement behaviour patterns and later clinically diagnosed obesity. Method In the population‐based All Babies in Southeast Sweden (ABIS) cohort, 16 415 children...